🚀 VC round data is live in beta, check it out!
Organogenesis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Organogenesis and similar public comparables like LENZ Therapeutics, Senores Pharmaceuticals, Cellectis, Greenwich LifeSciences and more.
Organogenesis Overview
About Organogenesis
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Founded
2018
HQ
Employees
869
Website
Sectors
Financials (LTM)
EV
$488M
Organogenesis Financials
Organogenesis reported last 12-month revenue of $521M and EBITDA of $77M.
In the same LTM period, Organogenesis generated $394M in gross profit, $77M in EBITDA, and $7M in net income.
Revenue (LTM)
Organogenesis P&L
In the most recent fiscal year, Organogenesis reported revenue of $563M and EBITDA of $98M.
Organogenesis expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $521M | XXX | $563M | XXX | XXX | XXX |
| Gross Profit | $394M | XXX | $426M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | $77M | XXX | $98M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $7M | XXX | $37M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 7% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Organogenesis Stock Performance
Organogenesis has current market cap of $380M, and enterprise value of $488M.
Market Cap Evolution
Organogenesis' stock price is $3.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $488M | $380M | 0.0% | XXX | XXX | XXX | $0.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOrganogenesis Valuation Multiples
Organogenesis trades at 0.9x EV/Revenue multiple, and 6.3x EV/EBITDA.
EV / Revenue (LTM)
Organogenesis Financial Valuation Multiples
As of April 6, 2026, Organogenesis has market cap of $380M and EV of $488M.
Equity research analysts estimate Organogenesis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Organogenesis has a P/E ratio of 53.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $380M | XXX | $380M | XXX | XXX | XXX |
| EV (current) | $488M | XXX | $488M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 6.3x | XXX | 5.0x | XXX | XXX | XXX |
| EV/EBIT | 17.7x | XXX | 8.7x | XXX | XXX | XXX |
| EV/Gross Profit | 1.2x | XXX | 1.1x | XXX | XXX | XXX |
| P/E | 53.9x | XXX | 10.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (20.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Organogenesis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Organogenesis Margins & Growth Rates
Organogenesis' revenue in the last 12 month declined by (18%).
Organogenesis' revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.4M for the same period.
Organogenesis' rule of 40 is (24%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Organogenesis' rule of X is (67%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Organogenesis Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (18%) | XXX | (29%) | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | (55%) | XXX | (82%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (24%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (67%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 66% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Organogenesis Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| LENZ Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Senores Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Cellectis | XXX | XXX | XXX | XXX | XXX | XXX |
| Greenwich LifeSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Benitec Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Organogenesis M&A Activity
Organogenesis acquired XXX companies to date.
Last acquisition by Organogenesis was on XXXXXXXX, XXXXX. Organogenesis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Organogenesis
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOrganogenesis Investment Activity
Organogenesis invested in XXX companies to date.
Organogenesis made its latest investment on XXXXXXXX, XXXXX. Organogenesis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Organogenesis
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Organogenesis
| When was Organogenesis founded? | Organogenesis was founded in 2018. |
| Where is Organogenesis headquartered? | Organogenesis is headquartered in United States. |
| How many employees does Organogenesis have? | As of today, Organogenesis has over 869 employees. |
| Who is the CEO of Organogenesis? | Organogenesis' CEO is Gary S. Gillheeney. |
| Is Organogenesis publicly listed? | Yes, Organogenesis is a public company listed on Nasdaq. |
| What is the stock symbol of Organogenesis? | Organogenesis trades under ORGO ticker. |
| When did Organogenesis go public? | Organogenesis went public in 2016. |
| Who are competitors of Organogenesis? | Organogenesis main competitors are LENZ Therapeutics, Senores Pharmaceuticals, Cellectis, Greenwich LifeSciences. |
| What is the current market cap of Organogenesis? | Organogenesis' current market cap is $380M. |
| What is the current revenue of Organogenesis? | Organogenesis' last 12 months revenue is $521M. |
| What is the current revenue growth of Organogenesis? | Organogenesis revenue growth (NTM/LTM) is (18%). |
| What is the current EV/Revenue multiple of Organogenesis? | Current revenue multiple of Organogenesis is 0.9x. |
| Is Organogenesis profitable? | Yes, Organogenesis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Organogenesis? | Organogenesis' last 12 months EBITDA is $77M. |
| What is Organogenesis' EBITDA margin? | Organogenesis' last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Organogenesis? | Current EBITDA multiple of Organogenesis is 6.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.